Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction
Author(s) -
Margaret M. Redfield,
Kevin J. Anstrom,
James A. Levine,
Gabe A. Koepp,
Barry A. Borlaug,
Horng H. Chen,
Martin M. LeWinter,
Susan Joseph,
Sanjiv J. Shah,
Marc J. Semigran,
G. Michael Felker,
Robert T. Cole,
Gordon R. Reeves,
Ryan J. Tedford,
W.H. Wilson Tang,
Steven E. McNulty,
Eric J. Velazquez,
Monica Shah,
Eugene Braunwald
Publication year - 2015
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1510774
Subject(s) - medicine , placebo , ejection fraction , isosorbide mononitrate , crossover study , isosorbide dinitrate , confidence interval , regimen , heart failure , clinical endpoint , cardiology , anesthesia , randomized controlled trial , alternative medicine , pathology
Nitrates are commonly prescribed to enhance activity tolerance in patients with heart failure and a preserved ejection fraction. We compared the effect of isosorbide mononitrate or placebo on daily activity in such patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom